{"title":"Immune checkpoint inhibitors in pediatric hematologic malignancies","authors":"I. Gribkova","doi":"10.17650/1818-8346-2023-18-2-25-34","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-2-25-34","url":null,"abstract":"The use of immune checkpoint inhibitors as therapy in adult patients with malignancy has resulted in an improvement in overall survival. Research on the use of these drugs in pediatric oncology is just beginning. However, the results already obtained indicate the possibility of successful use of checkpoint inhibitors in children with Hodgkin’s lymphoma and some subtypes of non-Hodgkin’s lymphomas. This review analyzes the results of studies on the use of nivolumab and pembrolizumab for the treatment of children with lymphomas. The search for available literature sources was carried out in the databases PubMed, Scopus, eLibrary, Cyberleninka. The review also addresses the issue of possible predictors of response to immune checkpoint inhibitor therapy in children.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90046370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expert Council Review “Multiple myeloma”","authors":"M. I. Akhmedov, P. A. Zeynalova","doi":"10.17650/1818-8346-2023-18-2-10-16","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-2-10-16","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82298688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Subbotina, I. Maslyukova, K. S. Semashchenko, G. Khodos, D. Kurochkin, A. A. Shalyova, M. Mikhalev, E. V. Vasiliev, M. Osadchaya, E. Dunaeva, A. Esman, K. Mironov
{"title":"Analysis of somatic mutations in the JAK2, CALR, MPL and ASXL1 genes and evaluation of their impact on the survival of patients with myelofibrosis","authors":"T. Subbotina, I. Maslyukova, K. S. Semashchenko, G. Khodos, D. Kurochkin, A. A. Shalyova, M. Mikhalev, E. V. Vasiliev, M. Osadchaya, E. Dunaeva, A. Esman, K. Mironov","doi":"10.17650/1818-8346-2023-18-1-63-75","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-63-75","url":null,"abstract":"Background. The development of myelofibrosis (MF) is driven by complex molecular genetic events that include driver somatic mutations responsible for the constitutive activation of the JAK/STAT signaling pathway (JAK2, CALR, and MPL), additional mutations affecting epigenetic regulators (TET2, ASXL1, IDH1/2, etc.) and RNA splicing (SRSF2, U2AF1, SF3B1, etc.), as well as genetic aberrations that contribute to genomic instability and disease progression.Aim. To analyze driver (JAK2, CALR, MPL) and prognostic (ASXL1) somatic mutations in patients with MF and evaluate their impact on survival.Materials and methods. The study included 29 patients diagnosed with MF, selected by hematologists from the City Clinical Hospital No. 7 and Regional Clinical Hospital (Krasnoyarsk).Results. 26 (89.6 %) out of 29 examined patients had some driver mutations in JAK2, CALR, MPL genes. The p.V617F mutation in the JAK2 gene was found in 20 (68.9 %) patients. Mutations in the CALR gene were detected in 4 (13.8 %) patients, mutations in the MPL gene were found in 3 patients (10.3 %). In 1 of 26 patients, 2 driver mutations were present simultaneously. 3 (10.3 %) patients were triple negative. Mutations in the ASXL1 gene were detected in 12 (41.4 %) out of 29 examined patients. Conducted targeted NGS (next generation sequencing) for 13 out of 29 patients revealed additional genetic variants that contribute to the understanding of the development mechanism and disease course. When evaluating the overall survival in the groups of patients diagnosed with MF examined by us, depending on the combination of driver (JAK2, CALR, MPL) and prognostic (ASXL1) mutations, no statistically significant differences were found (p = 0.12). This appears to be due to the small sample size. At the same time, assessment of patient survival depending on ASXL1 status showed that in the presence of mutations in the ASXL1 gene, the median survival was 45 months (range 7–120 months), while in the absence of mutations it was 48 months (range 21–359 months) (p = 0.03).Conclusion. The results obtained allow us to assume that the presence of mutations in the ASXL1 gene is an unfavorable factor in the course of the disease.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"150 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86150354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Klyasova, M. Akhmedov, L. Kuzmina, A. Fedorova, D. Mironova, E. Parovichnikova
{"title":"Risk of bloodstream infections in allogeneic hematopoietic cell transplant recipients according to gut mucosal colonization and fluoroquinolone implementation during neutropenia","authors":"G. Klyasova, M. Akhmedov, L. Kuzmina, A. Fedorova, D. Mironova, E. Parovichnikova","doi":"10.17650/1818-8346-2023-18-1-88-100","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-88-100","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73368961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1st line therapy for adult patients with diffuse large B-cell lymphoma","authors":"I. Dyakov","doi":"10.17650/1818-8346-2023-18-1-76-87","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-76-87","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80638861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment adherence in patients with blood system diseases and recipients of allogeneic organs and tissues","authors":"E. Kolgaeva, M. Drokov, D. Vybornykh","doi":"10.17650/1818-8346-2023-18-1-132-141","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-132-141","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90248506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Invasive mycoses in patients with hematological malignancies and recipients of hematopoietic stem cell transplantation: results of a systematic review, literature review and meta-analysis","authors":"M. Popova, Y. Rogacheva","doi":"10.17650/1818-8346-2023-18-1-101-120","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-101-120","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76497932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. I. Utesheva, T. Valiev, O. A. Ignatenko, S. V. Goryacheva, N. Batmanova, K. Kirgizov
{"title":"A clinical case of immune-mediated pneumonitis after nivolumab in a patient with Burkitt lymphoma","authors":"K. I. Utesheva, T. Valiev, O. A. Ignatenko, S. V. Goryacheva, N. Batmanova, K. Kirgizov","doi":"10.17650/1818-8346-2023-18-1-121-125","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-121-125","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73068245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Valiev, R. R. Fatkhullin, Yu. E. Ryabukhina, P. A. Zeynalova
{"title":"New drug formulations of colony-stimulating factors in oncohematology","authors":"T. Valiev, R. R. Fatkhullin, Yu. E. Ryabukhina, P. A. Zeynalova","doi":"10.17650/1818-8346-2023-18-1-126-131","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-1-126-131","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74206726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}